OTO-104 for Meniere's Disease

Otonomy logo

Otonomy

Status and phase

Completed
Phase 1

Conditions

Meniere's Disease

Treatments

Drug: OTO-104 (steroid) 3 mg
Drug: Placebo
Drug: OTO-104 (steroid) 12 mg

Study type

Interventional

Funder types

Industry

Identifiers

NCT01084525
104-200901

Details and patient eligibility

About

The purpose of this study is to evaluate the safety of OTO-104 in subjects with unilateral Meniere's disease. The effectiveness of OTO-104 to reduce the symptoms of Meniere's disease will also be evaluated.

Full description

Meniere's disease is a debilitating disorder of the inner ear which includes symptoms such as vertigo, tinnitus, hearing loss and aural fullness. Meniere's disease may result from an imbalance of fluid in the inner ear. Several studies have shown that corticosteroids may help manage this imbalance yet the effect does not last very long. OTO-104 is a longer lasting corticosteroid which could provide significant benefit to patients with Meniere's disease.

Enrollment

44 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Subject has a diagnosis of unilateral Meniere's disease by 1995 American Academy of Otolaryngology - Head and Neck Surgery (AAOHNS) criteria and reports active vertigo for the 2 months prior to the study lead-in period.
  2. Subject has experienced active vertigo during the lead-in period.
  3. Subject has asymmetric low frequency sensorineural hearing loss.
  4. Subject agrees to maintain their current treatments for Meniere's disease while on-study.
  5. Subjects not currently on a low-salt diet or diuretic should have a medical history of having used one or both of these treatments for at least 1 month without relief of symptoms.
  6. Subjects currently on a low-salt diet and/or diuretic at the time of screening agree to continue this treatment throughout the study.

Exclusion criteria

  1. Subject has an infection in the ear, sinuses, or upper respiratory system.
  2. Subject is pregnant or lactating.
  3. Subject has a history of immunodeficiency disease.
  4. Subject has a history of previous endolymphatic sac surgery.
  5. Subject has a history of previous use of intratympanic (IT) gentamicin in the affected ear.
  6. Subject has a history of tympanostomy tubes with evidence of perforation or lack of closure.
  7. Subject has experienced an adverse reaction to IT injection of steroids.
  8. Subject has used an investigational drug or device in the 3 months prior to screening.
  9. Subject has had a duration of Meniere's disease of >20 years.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

44 participants in 3 patient groups, including a placebo group

OTO-104 (steroid) 3 mg
Experimental group
Treatment:
Drug: OTO-104 (steroid) 3 mg
Placebo
Placebo Comparator group
Treatment:
Drug: Placebo
OTO-104 (steroid) 12 mg
Experimental group
Description:
The start of 12 mg dose cohort is contingent on safety data from 3 mg dose cohort.
Treatment:
Drug: OTO-104 (steroid) 12 mg

Trial contacts and locations

15

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems